Biocon signs Janssen licensing deal for Yesintek in nine additional markets

JNJ•2026-10-26

Biocon signed a licensing agreement with Janssen Sciences Ireland on October 26, 2026, granting immediate market entry rights for Yesintek in nine additional markets, including Australia, Brazil and China.

1. Licensing agreement

Biocon signed the agreement to commercialize Yesintek, its proposed Stelara biosimilar. The deal grants immediate market entry rights in nine additional markets, including Australia, Brazil and China.

Sources

Biocon signs Janssen licensing deal for Yesintek in nine additional markets

Docs

Biocon signs Janssen licensing deal for Yesintek in nine additional markets

1. Licensing agreement

Related News

Glacier Bancorp Inc: KBW raises target price to $56 from $55

Down by the River Thames, a failure to build holds back Britain's growth

Elections, central banks and earnings on the menu

Sources

Biocon signs Janssen licensing deal for Yesintek in nine additional markets

Molina Healthcare target price raised to $212 from $200

WSFS Financial Corporation: KBW raises target price to $91 from $89